GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Bioxyne Ltd (ASX:BXN) » Definitions » LT-Debt-to-Total-Asset

Bioxyne (ASX:BXN) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Bioxyne LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bioxyne's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Bioxyne's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).


Bioxyne LT-Debt-to-Total-Asset Historical Data

The historical data trend for Bioxyne's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxyne LT-Debt-to-Total-Asset Chart

Bioxyne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioxyne Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bioxyne LT-Debt-to-Total-Asset Calculation

Bioxyne's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )/Total Assets (A: Jun. 2023 )
=0/17.693
=0.00

Bioxyne's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0/4.737
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioxyne  (ASX:BXN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Bioxyne LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Bioxyne's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioxyne (ASX:BXN) Business Description

Traded in Other Exchanges
N/A
Address
50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. Some of its products include Breathe life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange etc. It operates in three segments: wholesale sales, Plant based and direct sales. The majority of the revenue is generated from Plant based in the United Kingdom, Europe and Japan.

Bioxyne (ASX:BXN) Headlines

No Headlines